Cannabinoid receptor type 1 protects nigrostriatal dopaminergic neurons against MPTP neurotoxicity by inhibiting microglial activation

Journal of Immunology

Volumn 187, Issue 12, 2011, Pages 6508-6517

  Chung, Young C ^a,f   Bok, Eugene ^a,d   Huh, Sue H ^a,b   Park, Ju Young ^c   Yoon, Sung Hwa ^c   Kim, Sang R ^a   Kim, Yoon Seong ^d   Maeng, Sungho ^e   Park, Sung Hyun ^e   Jin, Byung K ^a  

^a Kyung Hee University Hospital   (South Korea)

^b Ajou University School of Medicine   (South Korea)

^c Ajou University   (South Korea)

^d UNIVERSITY OF CENTRAL FLORIDA COLLEGE OF MEDICINE   (United States)

^e Kyung Hee University   (South Korea)

^f ROCKEFELLER UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 (2,4 DICHLOROPHENYL) 5 (4 IODOPHENYL) 4 METHYL N (1 PIPERIDYL) 1H PYRAZOLE 3 CARBOXAMIDE; 1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; 2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; CANNABINOID 1 RECEPTOR; DEXANABINOL; DOPAMINE; INTERLEUKIN 1BETA; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; TUMOR NECROSIS FACTOR ALPHA; TYROSINE 3 MONOOXYGENASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL ACTIVATION; CELL SURVIVAL; COCULTURE; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; IMMUNOHISTOCHEMISTRY; LOCOMOTION; MESENCEPHALON; MICROGLIA; MOUSE; NEUROPROTECTION; NEUROTOXICITY; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; ROTAROD TEST; STEREOLOGY; SUBSTANTIA NIGRA; UPREGULATION; WESTERN BLOTTING;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; ANIMALS; BENZOXAZINES; CELLS, CULTURED; COCULTURE TECHNIQUES; CORPUS STRIATUM; DOPAMINE AGENTS; GROWTH INHIBITORS; MALE; MICE; MICE, INBRED C57BL; MICROGLIA; MORPHOLINES; NAPHTHALENES; NEURONS; NEUROTOXINS; PARKINSONIAN DISORDERS; RECEPTOR, CANNABINOID, CB1; SUBSTANTIA NIGRA; TETRAHYDROCANNABINOL;

EID: 83755178512     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1102435     Document Type: Article

References (71)

1. Olanow, C. W., and W. G. Tatton. 1999. Etiology and pathogenesis of Parkinson's disease. Annu. Rev. Neurosci. 22: 123-144. (Pubitemid 29144883)
2. Savitt, J. M., V. L. Dawson, and T. M. Dawson. 2006. Diagnosis and treatment of Parkinson disease: molecules to medicine. J. Clin. Invest. 116: 1744-1754. (Pubitemid 44033293)
3. Hirsch, E. C., and S. Hunot. 2009. Neuroinflammation in Parkinson's disease: a target for neuroprotection? Lancet Neurol. 8: 382-397.
4. Chung, Y. C., S. R. Kim, and B. K. Jin. 2010. Paroxetine prevents loss of nigrostriatal dopaminergic neurons by inhibiting brain inflammation and oxidative stress in an experimental model of Parkinson's disease. J. Immunol. 185: 1230-1237.
5. Chung, Y. C., S. R. Kim, J. Y. Park, E. S. Chung, K. W. Park, S. Y. Won, E. Bok, M. Jin, E. S. Park, S. H. Yoon, et al. 2011. Fluoxetine prevents MPTP-induced loss of dopaminergic neurons by inhibiting microglial activation. Neuropharmacology 60: 963-974.
6. Liberatore, G. T., V. Jackson-Lewis, S. Vukosavic, A. S. Mandir, M. Vila, W. G. McAuliffe, V. L. Dawson, T. M. Dawson, and S. Przedborski. 1999. Inducible nitric oxide synthase stimulates dopaminergic neurodegeneration in the MPTP model of Parkinson disease. Nat. Med. 5: 1403-1409.
7. Wu, D. C., P. Teismann, K. Tieu, M. Vila, V. Jackson-Lewis, H. Ischiropoulos, and S. Przedborski. 2003. NADPH oxidase mediates oxidative stress in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease. Proc. Natl. Acad. Sci. USA 100: 6145-6150. (Pubitemid 36576945)
8. Mogi, M., M. Harada, H. Narabayashi, H. Inagaki, M. Minami, and T. Nagatsu. 1996. Interleukin (IL)-1 beta, IL-2, IL-4, IL-6 and transforming growth factoralpha levels are elevated in ventricular cerebrospinal fluid in juvenile parkinsonism and Parkinson's disease. Neurosci. Lett. 211: 13-16. (Pubitemid 26228016)
9. Hirsch, E. C., S. Hunot, P. Damier, and B. Faucheux. 1998. Glial cells and inflammation in Parkinson's disease: a role in neurodegeneration? Ann. Neurol. 44 (Suppl 1): S115-S120. (Pubitemid 28423837)
10. Ferger, B., A. Leng, A. Mura, B. Hengerer, and J. Feldon. 2004. Genetic ablation of tumor necrosis factor-alpha (TNF-alpha) and pharmacological inhibition of TNF-synthesis attenuates MPTP toxicity in mouse striatum. J. Neurochem. 89: 822-833. (Pubitemid 38684730)
11. Pott Godoy, M. C., R. Tarelli, C. C. Ferrari, M. I. Sarchi, and F. J. Pitossi. 2008. Central and systemic IL-1 exacerbates neurodegeneration and motor symptoms in a model of Parkinson's disease. Brain 131: 1880-1894. (Pubitemid 351957456)
12. Matsuda, L. A., S. J. Lolait, M. J. Brownstein, A. C. Young, and T. I. Bonner. 1990. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 346: 561-564.
13. Munro, S., K. L. Thomas, and M. Abu-Shaar. 1993. Molecular characterization of a peripheral receptor for cannabinoids. Nature 365: 61-65. (Pubitemid 23305569)
14. Chaperon, F., and M. H. Thiébot. 1999. Behavioral effects of cannabinoid agents in animals. Crit. Rev. Neurobiol. 13: 243-281. (Pubitemid 30265251)
15. Kim, S. R., D. Y. Lee, E. S. Chung, U. T. Oh, S. U. Kim, and B. K. Jin. 2005. Transient receptor potential vanilloid subtype 1 mediates cell death of mesencephalic dopaminergic neurons in vivo and in vitro. J. Neurosci. 25: 662-671.
16. Walter, L., A. Franklin, A. Witting, C. Wade, Y. Xie, G. Kunos, K. Mackie, and N. Stella. 2003. Nonpsychotropic cannabinoid receptors regulate microglial cell migration. J. Neurosci. 23: 1398-1405. (Pubitemid 36258918)
17. Bouaboula, M., B. Bourrié, M. Rinaldi-Carmona, D. Shire, G. Le Fur, and P. Casellas. 1995. Stimulation of cannabinoid receptor CB1 induces krox-24 expression in human astrocytoma cells. J. Biol. Chem. 270: 13973-13980.
18. Sánchez, C., I. Galve-Roperh, C. Canova, P. Brachet, and M. Guzmán. 1998. Delta9-tetrahydrocannabinol induces apoptosis in C6 glioma cells. FEBS Lett. 436: 6-10. (Pubitemid 28454597)
19. Molina-Holgado, E., J. M. Vela, A. Arévalo-Martín, G. Almazán, F. Molina-Holgado, J. Borrell, and C. Guaza. 2002. Cannabinoids promote oligodendrocyte progenitor survival: involvement of cannabinoid receptors and phosphatidylinositol-3 kinase/Akt signaling. J. Neurosci. 22: 9742-9753. (Pubitemid 35332857)
20. Devane, W. A., L. Hanus, A. Breuer, R. G. Pertwee, L. A. Stevenson, G. Griffin, D. Gibson, A. Mandelbaum, A. Etinger, and R. Mechoulam. 1992. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 258: 1946-1949. (Pubitemid 23026736)
21. Mechoulam, R., E. Fride, and V. Di Marzo. 1998. Endocannabinoids. Eur. J. Pharmacol. 359: 1-18. (Pubitemid 28515716)
22. Sugiura, T., S. Kondo, A. Sukagawa, S. Nakane, A. Shinoda, K. Itoh, A. Yamashita, and K. Waku. 1995. 2-Arachidonoylglycerol: a possible endogenous cannabinoid receptor ligand in brain. Biochem. Biophys. Res. Commun. 215: 89-97.
23. De Petrocellis, L., D. Melck, A. Palmisano, T. Bisogno, C. Laezza, M. Bifulco, and V. Di Marzo. 1998. The endogenous cannabinoid anandamide inhibits human breast cancer cell proliferation. Proc. Natl. Acad. Sci. USA 95: 8375-8380. (Pubitemid 28326120)
24. Pop, E. 1999. Cannabinoids, endogenous ligands and synthetic analogs. Curr. Opin. Chem. Biol. 3: 418-425. (Pubitemid 29376103)
25. Sarfaraz, S., F. Afaq, V. M. Adhami, and H. Mukhtar. 2005. Cannabinoid receptor as a novel target for the treatment of prostate cancer. Cancer Res. 65: 1635-1641. (Pubitemid 40478586)
26. Cannizzaro, C., M. D'Amico, P. Preziosi, and M. Martire. 2006. Presynaptic effects of anandamide and WIN55,212-2 on glutamatergic nerve endings isolated from rat hippocampus. Neurochem. Int. 48: 159-165. (Pubitemid 43083618)
27. Mackie, K. 2005. Distribution of cannabinoid receptors in the central and peripheral nervous system. Handb. Exp. Pharmacol. 168: 299-325.
28. Cristino, L., L. de Petrocellis, G. Pryce, D. Baker, V. Guglielmotti, and V. Di Marzo. 2006. Immunohistochemical localization of cannabinoid type 1 and vanilloid transient receptor potential vanilloid type 1 receptors in the mouse brain. Neuroscience 139: 1405-1415.
29. van der Stelt, M., W. B. Veldhuis, G. W. van Haaften, F. Fezza, T. Bisogno, P. R. Bar, G. A. Veldink, J. F. Vliegenthart, V. Di Marzo, and K. Nicolay. 2001. Exogenous anandamide protects rat brain against acute neuronal injury in vivo. J. Neurosci. 21: 8765-8771. (Pubitemid 33054840)
30. Docagne, F., V. Muñetón, D. Clemente, C. Ali, F. Loría, F. Correa,M. Hernangómez, L. Mestre, D. Vivien, and C. Guaza. 2007. Excitotoxicity in a chronic model of multiple sclerosis: Neuroprotective effects of cannabinoids through CB1 and CB2 receptor activation. Mol. Cell. Neurosci. 34: 551-561 (Pubitemid 46483078)
31. Melis, M., G. Pillolla, T.Bisogno, A. Minassi, S. Petrosino, S. Perra, A. L. Muntoni, B. Lutz, G. L. Gessa, G. Marsicano, et al. 2006. Protective activation of the endocannabinoid system during ischemia in dopamine neurons. Neurobiol. Dis. 24: 15-27. (Pubitemid 44416209)
32. González, S., C. Scorticati, M. García-Arencibia, R. de Miguel, J. A. Ramos, and J. Fernández-Ruiz. 2006. Effects of rimonabant, a selective cannabinoid CB1 receptor antagonist, in a rat model of Parkinson's disease. Brain Res. 1073-1074: 209-219.
33. Kelsey, J. E., O. Harris, and J. Cassin. 2009. The CB(1) antagonist rimonabant is adjunctively therapeutic as well as monotherapeutic in an animal model of Parkinson's disease. Behav. Brain Res. 203: 304-307.
34. Pisani, A., F. Fezza, S. Galati, N. Battista, S. Napolitano, A. Finazzi-Agrò, G. Bernardi, L. Brusa, M. Pierantozzi, P. Stanzione, and M. Maccarrone. 2005. High endogenous cannabinoid levels in the cerebrospinal fluid of untreated Parkinson's disease patients. Ann. Neurol. 57: 777-779. (Pubitemid 40628874)
35. Gubellini, P., B. Picconi, M. Bari, N. Battista, P. Calabresi, D. Centonze, G. Bernardi, A. Finazzi-Agrò, and M. Maccarrone. 2002. Experimental parkinsonism alters endocannabinoid degradation: implications for striatal glutamatergic transmission. J. Neurosci. 22: 6900-6907. (Pubitemid 35379148)
36. van der Stelt, M., S. H. Fox, M. Hill, A. R. Crossman, S. Petrosino, V. Di Marzo, and J. M. Brotchie. 2005. A role for endocannabinoids in the generation of parkinsonism and levodopa-induced dyskinesia in MPTP-lesioned non-human primate models of Parkinson's disease. FASEB J. 19: 1140-1142. (Pubitemid 40946444)
37. Lastres-Becker, I., F. Molina-Holgado, J. A. Ramos, R. Mechoulam, and J. Fernández-Ruiz. 2005. Cannabinoids provide neuroprotection against 6-hydroxydopamine toxicity in vivo and in vitro: relevance to Parkinson's disease. Neurobiol. Dis. 19: 96-107. (Pubitemid 40544727)
38. Lee, S., D. H. Kim, S. H. Yoon, and J. H. Ryu. 2009. Sub-chronic administration of rimonabant causes loss of antidepressive activity and decreases doublecortin immunoreactivity in the mouse hippocampus. Neurosci. Lett. 467: 111-116.
39. Ramírez, B. G., C. Blázquez, T. Gómez del Pulgar, M. Guzmán, and M. L. de Ceballos. 2005. Prevention of Alzheimer's disease pathology by cannabinoids: neuroprotection mediated by blockade of microglial activation. J. Neurosci. 25: 1904-1913. (Pubitemid 40289395)
40. West, M. J., L. Slomianka, and H. J. Gundersen. 1991. Unbiased stereological estimation of the total number of neurons in thesubdivisions of the rat hippocampus using the optical fractionator. Anat. Rec. 231: 482-497.
41. Przedborski, S., V. Jackson-Lewis, R. Djaldetti, G. Liberatore, M. Vila, S. Vukosavic, and G. Almer. 2000. The parkinsonian toxin MPTP: action and mechanism. Restor. Neurol. Neurosci. 16: 135-142. (Pubitemid 30159159)
42. Price, D. A., A. A. Martinez, A. Seillier, W. Koek, Y. Acosta, E. Fernandez, R. Strong, B. Lutz, G. Marsicano, J. L. Roberts, and A. Giuffrida. 2009. WIN55,212-2, a cannabinoid receptor agonist, protects against nigrostriatal cell loss in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease. Eur. J. Neurosci. 29: 2177-2186.
43. Babior, B. M. 2004. NADPH oxidase. Curr. Opin. Immunol. 16: 42-47. (Pubitemid 38198116)
44. Cross, A. R., and A. W. Segal. 2004. The NADPH oxidase of professional phagocytes-prototype of the NOX electron transport chain systems. Biochim. Biophys. Acta 1657: 1-22. (Pubitemid 38823040)
45. Isobe, C., T. Abe, and Y. Terayama. 2010. Levels of reduced and oxidized coenzyme Q-10 and 8-hydroxy-2′-deoxyguanosine in the cerebrospinal fluid of patients with living Parkinson's disease demonstrate that mitochondrial oxidative damage and/or oxidative DNA damage contributes to the neurodegenerative process. Neurosci. Lett. 469: 159-163.
46. Alam, Z. I., S. E. Daniel, A. J. Lees, D. C. Marsden, P. Jenner, and B. Halliwell. 1997. A generalised increase in protein carbonyls in the brain in Parkinson's but not incidental Lewy body disease. J. Neurochem. 69: 1326-1329. (Pubitemid 27364859)
47. Beal, M. F. 1998. Excitotoxicity and nitric oxide in Parkinson's disease pathogenesis. Ann. Neurol. 44(Suppl 1): S110-S114. (Pubitemid 28423836)
48. Martín-Moreno, A. M., D. Reigada, B. G. Ramírez, R. Mechoulam, N. Innamorato, A. Cuadrado, and M. L. de Ceballos. 2011. Cannabidiol and other cannabinoids reduce microglial activation in vitro and in vivo: relevance to Alzheimer's disease. Mol. Pharmacol. 79: 964-973.
49. Centonze, D., A. Finazzi-Agrò, G. Bernardi, and M. Maccarrone. 2007. The endocannabinoid system in targeting inflammatory neurodegenerative diseases. Trends Pharmacol. Sci. 28: 180-187.
50. Kreitzer, A. C., and R. C. Malenka. 2007. Endocannabinoid-mediated rescue of striatal LTD and motor deficits in Parkinson's disease models. Nature 445: 643-647. (Pubitemid 46232883)
51. Fernandez-Ruiz, J., M. Moreno-Martet, C. Rodriguez-Cueto, C. Palomo-Garo, M. Gomez-Canas, S. Valdeolivas, C. Guaza, J. Romero,M. Guzman, R. Mechoulam, and J. A. Ramos. 2011. Prospects for cannabinoid therapies in basal ganglia disorders. Br. J. Pharmacol. 163: 1365-1378.
52. Morgese, M. G., T. Cassano, V. Cuomo, and A. Giuffrida. 2007. Anti-dyskinetic effects of cannabinoids in a rat model of Parkinson's disease: role of CB(1) and TRPV1 receptors. Exp. Neurol. 208: 110-119. (Pubitemid 47600153)
53. Sañudo-Peña, M. C., K. Tsou, and J. M. Walker. 1999. Motor actions of cannabinoids in the basal ganglia output nuclei. Life Sci. 65: 703-713. (Pubitemid 29362776)
54. Chevaleyre, V., K. A. Takahashi, and P. E. Castillo. 2006. Endocannabinoid-mediated synaptic plasticity in the CNS. Annu. Rev. Neurosci. 29: 37-76. (Pubitemid 44476839)
55. Piomelli, D. 2003. The molecular logic of endocannabinoid signalling. Nat. Rev. Neurosci. 4: 873-884. (Pubitemid 37351427)
56. Molina-Holgado, F., E. Pinteaux, J. D. Moore, E. Molina-Holgado, C. Guaza, R. M. Gibson, and N. J. Rothwell. 2003. Endogenous interleukin-1 receptor antagonist mediates anti-inflammatory and neuroprotective actions of cannabinoids in neurons and glia. J. Neurosci. 23: 6470-6474. (Pubitemid 36909872)
57. Sancho, R., M. A. Calzado, V. Di Marzo, G. Appendino, and E. Muñoz. 2003. Anandamide inhibits nuclear factor-kappaB activation through a cannabinoid receptor-independent pathway. Mol. Pharmacol. 63: 429-438. (Pubitemid 36158379)
58. Walter, L., and N. Stella. 2004. Cannabinoids and neuroinflammation. Br. J. Pharmacol. 141: 775-785. (Pubitemid 38446178)
59. Kim, S. U., and J. de Vellis. 2005. Microglia in health and disease. J. Neurosci. Res. 81: 302-313. (Pubitemid 41359284)
60. Block, M. L., L. Zecca, and J. S. Hong. 2007. Microglia-mediated neurotoxicity: uncovering the molecular mechanisms. Nat. Rev. Neurosci. 8: 57-69. (Pubitemid 46011999)
61. Beal, M. F. 2002. Oxidatively modified proteins in aging and disease. Free Radic. Biol. Med. 32: 797-803. (Pubitemid 34439250)
62. Fahn, S., and G. Cohen. 1992. The oxidant stress hypothesis in Parkinson's disease: evidence supporting it. Ann. Neurol. 32: 804-812.
63. Miller, R. L., M. James-Kracke, G. Y. Sun, and A. Y. Sun. 2009. Oxidative and inflammatory pathways in Parkinson's disease. Neurochem. Res. 34: 55-65.
64. Oyagi, A., Y. Oida, H. Hara, H. Izuta, M. Shimazawa, N. Matsunaga, T. Adachi, and H. Hara. 2008. Protective effects of SUN N8075, a novel agent with anti-oxidant properties, in in vitro and in vivo models of Parkinson's disease. Brain Res. 1214: 169-176.
65. Zhang, J., G. Perry, M. A. Smith, D. Robertson, S. J. Olson, D. G. Graham, and T. J. Montine. 1999. Parkinson's disease is associated with oxidative damage to cytoplasmic DNA and RNA in substantia nigra neurons. Am. J. Pathol. 154: 1423-1429. (Pubitemid 29226437)
66. Block, M. L., and J. S. Hong. 2007. Chronic microglial activation and progressive dopaminergic neurotoxicity. Biochem. Soc. Trans. 35: 1127-1132. (Pubitemid 350206444)
67. Gao, H. M., B. Liu, W. Zhang, and J. S. Hong. 2003. Critical role of microglial NADPH oxidase-derived free radicals in the in vitro MPTP model of Parkinson's disease. FASEB J. 17: 1954-1956.
68. Nagatsu, T., and M. Sawada. 2007. Biochemistry of postmortem brains in Parkinson's disease: historical overview and future prospects. J. Neural Transm. Suppl. 72: 113-120.
69. Zhao, C., Z. Ling, M. B. Newman, A. Bhatia, and P. M. Carvey. 2007. TNF-alpha knockout and minocycline treatment attenuates blood-brain barrier leakage in MPTP-treated mice. Neurobiol. Dis. 26: 36-46. (Pubitemid 46437443)
70. Teismann, P., K. Tieu, O. Cohen, D. K. Choi, D. C. Wu, D. Marks, M. Vila, V. Jackson-Lewis, and S. Przedborski. 2003. Pathogenic role of glial cells in Parkinson's disease. Mov. Disord. 18: 121-129. (Pubitemid 36305454)
71. Jackson-Lewis, V., and S. Przedborski. 2007. Protocol for the MPTP mouse model of Parkinson's disease. Nat. Protoc. 2: 141-151 (Pubitemid 47044700)